Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Feb 1.

Published in final edited form as: J Hepatol. 2021 Oct 14;76(2):275–282. doi: 10.1016/j.jhep.2021.10.005

Table 1.

Score construction and validation plan.

		Cohorts available for independent validation
		GenomALC-1 (N=1690)	GenomALC-2 (N=3037)	UK Biobank (N=6898)
1	3-SNP score, using SNPs and coefficients from initial reports^17,18 = (0.7839PNPLA3* rs738409 G dosage) + (0.5423*SUGP1-TM6SF2 rs10401969 C dosage) − (0.4463*HSD17B13 rs6834314 G dosage)**	Yes	Yes	Yes
2	3-SNP score as in 1 above, with addition of BMI and coffee = *[1] + (0.0709BMI) − (0.645Coffee)*	No (BMI and coffee coefficients are derived from this cohort)	No (no information of BMI and coffee)	Yes
3	3-SNP-M score, using SNPs and coefficients from meta-analysis²⁰ = (0.7274PNPLA3* rs2294915 T dosage) + (0.3988*SUGP1 rs10401969 C dosage) − (0.2485*HSD17B13 rs10433937 G dosage)**	No^*	Yes	No^*
4	5-SNP-M score; as in 3 above but with addition of two GW-significant SNPs from meta-analysis = [3] + (0.6419SERPINA1* rs28929474 T dosage) − (0.2357*FAF2 rs11134997 C dosage)**	No^*	Yes	No^*
5	8-SNP-M score; as in 4 but with three additional SNPs with genome-wide significant associations with alcohol-related liver disease = [4] + (0.1446MBOAT7* rs641738 T dosage) − (0.2401*MTARC1 rs2642438 A dosage) − (0.1304*HNRNPUL1 rs17251589 T dosage)**	No^*	Yes	No^*

^*

SNP coefficients are derived from this cohort